dpp-4 inhibitors vs. glp-1 agonist receptor versus inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes DPP-4 inhibitors and GLP-1RAs: cardiovascular

Concerns have been expressed regarding the effects of these drugs on pancreatic and thyroid tissue, since animal studies and analyses of drug databases indicate an association of GLP-1 receptor agonists with pancreatitis, pancreatic cancer, and thyroid cancer

Multinational manufacturers are establishing commercial presence while domestic players advance biosimilar and next-generation programs

doi: 10.1111/dom.12849 32 SimRChongCWLoganadanNKFongAYYNavaravongLHusseinZet al

Politics1 year ago Which Types of Government Rule the World

These results are the basis for a positioning of the DPP-4 inhibitors as second-line therapy for the treatment of type 2 diabetes, especially, when hypoglycaemia should strictly be avoided (see section below)